Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Shitara
Kohei
K
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. kouheis0824@yahoo.co.jp
Yokota
Tomoya
T
Takahari
Daisuke
D
Shibata
Takashi
T
Ura
Takashi
T
Komatsu
Yoshito
Y
Yuki
Satoshi
S
Yoshida
Motoki
M
Takiuchi
Hiroya
H
Utsunomiya
Setsuo
S
Yatabe
Yasushi
Y
Muro
Kei
K
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D002985:Clinical Protocols; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D000077146:Irinotecan; D009362:Neoplasm Metastasis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002166:Camptothecin